Sumarsono A, Everett BM, McGuire DK, et al. - Experts intended to assess trends, among US Medicare Part D beneficiaries from 2012 to 2017, in aggregate use and expenditures for all DM therapies. There were, at present, 12 classes of antihyperglycemic medications accessible for patients with T2DM. The relative distribution of expenses across DM therapeutic classes requires to be reinvestigated, along with an estimated 30 million individuals in the United States living with T1DM and rising complexity and financial burden of DM care.